Advanced

Evaluating vacquinol-1 in rats carrying glioblastoma models RG2 and NS1

Ahlstedt, Jonatan LU ; Förnvik, Karolina LU ; Zolfaghari, Shaian; Kwak, Dongoh; Hammarström, Lars G.J.; Ernfors, Patrik; Salford, Leif G. LU and Nittby Redebrandt, Henrietta LU (2018) In Oncotarget 9(9). p.8391-8399
Abstract

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, and available experimental and routine therapies result in limited survival benefits. A vulnerability of GBM cells to catastrophic vacuolization and cell death, a process termed methuosis, induced by Vacquinol-1 (VQ-1) has been described earlier. In the present study, we investigate the efficacy of VQ-1 treatment in two syngeneic rat GBM models, RG2 and NS1. VQ-1 treatment affected growth of both RG2 and NS1 cells in vitro. Intracranially, significant reduction in RG2 tumor size was observed, although no effect was seen on overall survival. No survival advantage or effect on tumor size was seen in animals carrying the NS1 models compared to untreated... (More)

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, and available experimental and routine therapies result in limited survival benefits. A vulnerability of GBM cells to catastrophic vacuolization and cell death, a process termed methuosis, induced by Vacquinol-1 (VQ-1) has been described earlier. In the present study, we investigate the efficacy of VQ-1 treatment in two syngeneic rat GBM models, RG2 and NS1. VQ-1 treatment affected growth of both RG2 and NS1 cells in vitro. Intracranially, significant reduction in RG2 tumor size was observed, although no effect was seen on overall survival. No survival advantage or effect on tumor size was seen in animals carrying the NS1 models compared to untreated controls. Furthermore, immunological staining of FOXP3, CD4 and CD8 showed no marked difference in immune cell infiltrate in tumor environment following treatment. Taken together, a survival advantage of VQ-1 treatment alone could not be demonstrated here, even though some effect upon tumor size was seen. Staining for immune cell markers did not indicate that VQ-1 either reduced or increased host anti-tumor immune response.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Glioblastoma, NS1, Rat, RG2, Vacquinol-1
in
Oncotarget
volume
9
issue
9
pages
8391 - 8399
publisher
Impact Journals, LLC
external identifiers
  • scopus:85041482040
ISSN
1949-2553
DOI
10.18632/oncotarget.23842
language
English
LU publication?
yes
id
b3fa0e25-d2ef-459f-805f-59fa2893702b
date added to LUP
2018-02-21 14:43:50
date last changed
2018-05-29 09:46:57
@article{b3fa0e25-d2ef-459f-805f-59fa2893702b,
  abstract     = {<p>Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, and available experimental and routine therapies result in limited survival benefits. A vulnerability of GBM cells to catastrophic vacuolization and cell death, a process termed methuosis, induced by Vacquinol-1 (VQ-1) has been described earlier. In the present study, we investigate the efficacy of VQ-1 treatment in two syngeneic rat GBM models, RG2 and NS1. VQ-1 treatment affected growth of both RG2 and NS1 cells in vitro. Intracranially, significant reduction in RG2 tumor size was observed, although no effect was seen on overall survival. No survival advantage or effect on tumor size was seen in animals carrying the NS1 models compared to untreated controls. Furthermore, immunological staining of FOXP3, CD4 and CD8 showed no marked difference in immune cell infiltrate in tumor environment following treatment. Taken together, a survival advantage of VQ-1 treatment alone could not be demonstrated here, even though some effect upon tumor size was seen. Staining for immune cell markers did not indicate that VQ-1 either reduced or increased host anti-tumor immune response.</p>},
  author       = {Ahlstedt, Jonatan and Förnvik, Karolina and Zolfaghari, Shaian and Kwak, Dongoh and Hammarström, Lars G.J. and Ernfors, Patrik and Salford, Leif G. and Nittby Redebrandt, Henrietta },
  issn         = {1949-2553},
  keyword      = {Glioblastoma,NS1,Rat,RG2,Vacquinol-1},
  language     = {eng},
  number       = {9},
  pages        = {8391--8399},
  publisher    = {Impact Journals, LLC},
  series       = {Oncotarget},
  title        = {Evaluating vacquinol-1 in rats carrying glioblastoma models RG2 and NS1},
  url          = {http://dx.doi.org/10.18632/oncotarget.23842},
  volume       = {9},
  year         = {2018},
}